Screening for factor V Leiden mutation before prescribing combination oral contraceptives

Mitchell D Creinin, Rachel Lisman, Ronald C. Strickler

Research output: Contribution to journalArticle

75 Scopus citations

Abstract

Objective: To evaluate the cost-effectiveness of screening for factor V Leiden mutation in women in the United States who use combination oral contraceptives. Design: Cost-effectiveness analysis. Setting: A national research reference laboratory, a university medical center, and an academic health center managed care organization. Patient(s): Women of reproductive age in the United States. Intervention(s): Baseline risk estimates of venous thromboembolic disease in the general population and in carriers of factor V Leiden mutation were calculated using available data. Main Outcome Measure(s): The number of women who would require factor V Leiden testing and the cost of identifying this cohort to prevent one death caused by venous thromboembolic disease before prescribing combination oral contraceptives. Result(s): To prevent one venous thromboembolic death attributable to the use of oral contraceptives in women with factor V Leiden mutation, >92,000 carriers would need to be identified and stopped from using these pills. The estimated charge to prevent this one death would exceed $300 million. If the price of testing were discounted to 34.5% of current charges, the cost still would be between $105 million and $130 million. Conclusion(s): Screening for factor V Leiden mutation before prescribing combination oral contraceptives is not a cost-effective use of U.S. health care dollars. The best and most cost-effective screening tool we have is taking a thorough personal and family history related to venous thromboembolic events.

Original languageEnglish (US)
Pages (from-to)646-651
Number of pages6
JournalFertility and Sterility
Volume72
Issue number4
DOIs
StatePublished - Oct 1999
Externally publishedYes

    Fingerprint

Keywords

  • Factor V Leiden
  • Hypercoagulability
  • Oral contraceptives
  • Venous thromboembolism

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this